Isofol Medical

Company Description

---

Isofol Medical AB (publ), founded in 2008, is a biotech company that is developing a new drug candidate for the treatment of advanced colorectal cancer.

Colorectal cancer (CRC) is the third most common form of cancer worldwide and there is a very high need for more effective drugs to treat this disease.

Vision:
“Isofol will help extend life and improve the quality of life for cancer patients”

Arfolitixorin is being developed and commercialized through a global licensing agreement with Merck & Cie in Germany. The licensing agreement also grants Isofol access to the unique patented manufacturing process for arfolitixorin.

Year founded

---

2008

Headquarters

---

Arvid Wallgrens Backe 20, 41346 Gothenburg – Sweden

Shares outstanding

---

161,515,440

IPO

---

Jan. 1, 2000

Stock exchange(s)

---

Nasdaq Stockholm